Semaglutide · 3 min read
The five-step, sixteen-week ladder to 2.4 mg — what each rung does, the missed-dose rules, why 1.7 mg is a real maintenance dose, and how dose caps quietly change what a price buys.
The five-step, sixteen-week ladder to 2.4 mg — what each rung does, the missed-dose rules, why 1.7 mg is a real maintenance dose, and how dose caps quietly change what a price buys.
Semaglutide's weight-management ladder runs 0.25 mg weekly for four weeks, then 0.5, 1.0, 1.7, and 2.4 mg in four-week steps — about sixteen weeks to full dose. The first rung is purely an on-ramp; therapeutic effect builds meaningfully from 0.5–1.0 mg, and the trial evidence base (STEP program, 14.9% average loss) describes the 2.4 mg destination.
The four-week spacing matches the drug's week-long half-life: each step needs about a month to reach steady state, and GI side effects cluster in the days after each increase. Escalation is not mandatory on schedule — holding a rung an extra month for tolerability is standard practice, and some patients maintain long-term at 1.7 mg with good response. The label's fallback runs the same direction: if 2.4 mg isn't tolerated, dropping to 1.7 mg for a period is an approved move. The pattern to avoid is the opposite one — staying at 0.5–1.0 mg by default and concluding the drug "doesn't work" at doses the obesity trials never tested as endpoints.
A missed weekly dose: take it within five days, otherwise skip and resume schedule. Dose-day changes are fine with at least two days (48 hours) between injections. Sites rotate among abdomen, thigh, upper arm. Oral semaglutide plays by different rules entirely — empty stomach, plain water, a 30-minute wait — covered in the Wegovy pill explainer.
Three market patterns to check before buying. Flat-rate programs (NexLife $145–$165, Mochi $178 all-in, SkinnyRx $199, Enhance.MD by term) charge the same at 0.5 and 2.4 mg, so titration is cost-neutral. Dose- or format-scaled programs (ShedRx, MEDVi's format tiers) climb as you do. And dose-capped programs are the trap dressed as a deal: Noom's $199 buys a 0.6 mg maximum — a quarter of the trial dose — which is not the same product at a nicer price; it is a different product. Brand Wegovy sidesteps all of it with one number: $349 at every injectable dose through NovoCare. Every program's dose structure is flagged in the pricing database.
Titration pace and maintenance dose are clinical decisions made with your prescriber; the ladder above is the labeled framework, not a personal schedule.
The labeled target is 2.4 mg weekly (reached around week 17), with 1.7 mg an approved fallback that many patients maintain on successfully.
Take it within five days of the missed dose; beyond that, skip it and resume your schedule, keeping at least 48 hours between any two injections.
Because it delivers a quarter of the trial-studied dose. Dose-capped programs price below the market precisely because they are not offering the full-dose product the STEP results describe.